September 8, 2011 — Naviscan announced it obtained CE Mark approval for its high-resolution positron emission tomography (PET) scanner and PET-guided biopsy accessory. The breast application of the scanner is positron emission mammography (PEM). Naviscan has expanded its distribution into 13 European countries and has already received its first two orders in Germany and Switzerland.

The company manufactures the only commercially available, high-resolution PET scanner with PET-guided biopsy system. The scanner uses PET technology to produce tomographic images allowing physicians to visualize breast tumors with an unprecedented resolution of 1.6 mm, about the width of a grain of rice.

In recently published data, PEM has been found to be significantly more precise than existing technologies at identifying benign and cancerous lesions, in what scientists call "specificity." This reduces the number of unnecessary biopsies. It is a welcomed outcome for women and physicians looking to reduce patient trauma and cost associated with unnecessary procedures.

The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the United States and other parts of the world.

For more information: www.naviscan.com


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Breast Imaging

April 2, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced ...

Time April 02, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Breast Imaging

March 20, 2024 — Interval breast cancer is one that appears between two reviews of a screening program. That is, it is ...

Time March 20, 2024
arrow
News | Breast Imaging

March 15, 2024 — Screening-detected radial scars without atypia at core-needle biopsy (CNB) have a low upstaging rate to ...

Time March 15, 2024
arrow
News | Breast Imaging

March 6, 2024 — There is a pressing need to explore and understand which social determinants of health (SDOH) and health ...

Time March 06, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
Subscribe Now